References
- Van OsJKapurSLancet200937463564519700006
- World Health OrganizationSchizophrenia Available from: http://www.who.int/mental_health/management/schizophrenia/en/Accessed February 27, 2011
- PhillipsMZhangJXShiQCPrevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–2005: an epidemiological surveyLancet20093732041205319524780
- LeuchtSBarnesTRKisslingWEngelRRCorrellCKaneJMRelapse prevention in schizophrenia with new generation antipsychotics: a systematic review and exploratory meta analysis of randomized, controlled trialsAm J Psychiatry20031601209122212832232
- CorriganPWLibermanRPEngelJDFrom noncompliance to collaboration in the treatment of schizophreniaHosp Community Psychiatry199041120312111979044
- LacroJPDunnLBDolderCRLeckbandSGJesteDVPrevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literatureJ Clin Psychiatry20026389290912416599
- ChuePJonesBTaylorCCDicksonRDissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophreniaCan J Psychiatry20024777177412420656
- HsuWYHuangSSLeeBSChiuNYComparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in TaiwanJ Clin Psychopharmacol20103023023420473056
- KinonBJHillALLiuHKollack-WalkerSOlanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophreniaInt J Neuropsychopharmacol200369710212890301